Abstract
Overexpression of the ErbB2 receptor tyrosine kinase in breast cancer contributes to tumor development and is associated with poor prognosis. However, the mechanism by which ErbB2 might contribute to metastasis is not well defined. To identify genes that mediate ErbB2-driven cell motility, we performed differential gene expression analysis of ErbB2-expressing migrating breast cancer cells vs mutant ErbB2-expressing non-migrating cells. Among the genes that were specifically induced in migrating cells were known transcriptional targets of ErbB2, such as matrix metalloproteinases, and novel ErbB2 targets. Contribution of selected candidate genes to ErbB2-driven cell motility was tested by small interfering RNA targeting. Knockdown of the soluble form of ST2 (sST2), also called interleukin-1 receptor-like 1, one of the most robustly induced genes, decreased ErbB2-induced cell motility in two different cell lines. In response to ErbB2 activation, sST2 protein expression and secretion were increased. Moreover, recombinant sST2 associated with the plasma membrane and sST2-blocking antibodies reduced ErbB2-induced motility. Interestingly, cells from metastatic breast tumors secreted higher levels of sST2 than primary tumor cells. Finally, sST2 was found at high levels in the serum of metastatic breast cancer patients. Our data suggest that sST2 contributes to breast cancer cell motility and that sST2 secretion is associated with metastasis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M et al. (2005). FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Biol 171: 505–516.
Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M . (1994). Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 13: 1176–1188.
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353–357.
Bosc DG, Goueli BS, Janknecht R . (2001). HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene 20: 6215–6224.
Brunner M, Krenn C, Roth G, Moser B, Dworschak M, Jensen-Jarolim E et al. (2004). Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 30: 1468–1473.
Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F et al. (2006). Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol 169: 268–278.
Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N et al. (2006). Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25: 2273–2284.
Dankort D, Maslikowski B, Warner N, Kanno N, Kim H, Wang Z et al. (2001). Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Mol Cell Biol 21: 1540–1551.
Dufour A, Sampson NS, Zucker S, Cao J . (2008). Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol 217: 643–651.
Eisen MB, Spellman PT, Brown PO, Botstein D . (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863–14868.
Fabre S, Reymond N, Cocchi F, Menotti L, Dubreuil P, Campadelli-Fiume G et al. (2002). Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C’-C’-D beta-strands of the nectin1V domain. J Biol Chem 277: 27006–27013.
Gayle MA, Slack JL, Bonnert TP, Renshaw BR, Sonoda G, Taguchi T et al. (1996). Cloning of a putative ligand for the T1/ST2 receptor. J Biol Chem 271: 5784–5789.
Grossmann KS, Wende H, Paul FE, Cheret C, Garratt AN, Zurborg S et al. (2009). The tyrosine phosphatase Shp2 (PTPN11) directs neuregulin-1/ErbB signaling throughout Schwann cell development. Proc Natl Acad Sci USA 106: 16704–16709.
Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ . (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578–10582.
Hayakawa H, Hayakawa M, Kume A, Tominaga S . (2007). Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 282: 26369–26380.
Hijazi MM, Thompson EW, Tang C, Coopman P, Torri JA, Yang D et al. (2000). Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. Int J Oncol 17: 629–641.
Ho IA, Chan KY, Ng WH, Guo CM, Hui KM, Cheang P et al. (2009). Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 27: 1366–1375.
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249–264.
Jarry A, Dorso L, Gratio V, Forgue-Lafitte ME, Laburthe M, Laboisse CL et al. (2007). PAR-2 activation increases human intestinal mucin secretion through EGFR transactivation. Biochem Biophys Res Commun 364: 689–694.
Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A . (2002). The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 4: 540–544.
Kakkar R, Lee RT . (2008). The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7: 827–840.
Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, Arteaga CL et al. (2009). ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clin Cancer Res 15: 3733–3739.
Klemenz R, Hoffmann S, Werenskiold AK . (1989). Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci USA 86: 5708–5712.
Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E et al. (1998). Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 18: 7095–7105.
Marone R, Hess D, Dankort D, Muller WJ, Hynes NE, Badache A . (2004). Memo mediates ErbB2-driven cell motility. Nat Cell Biol 6: 515–522.
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M et al. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274.
Mazumdar A, Adam L, Boyd D, Kumar R . (2001). Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion. Cancer Res 61: 400–405.
Meisel C, Bonhagen K, Lohning M, Coyle AJ, Gutierrez-Ramos JC, Radbruch A et al. (2001). Regulation and function of T1/ST2 expression on CD4+ T cells: induction of type 2 cytokine production by T1/ST2 cross-linking. J Immunol 166: 3143–3150.
Michl P, Ramjaun AR, Pardo OE, Warne PH, Wagner M, Poulsom R et al. (2005). CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7: 521–532.
Morris DR, Ding Y, Ricks TK, Gullapalli A, Wolfe BL, Trejo J . (2006). Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res 66: 307–314.
Olayioye MA, Neve RM, Lane HA, Hynes NE . (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19: 3159–3167.
Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S et al. (2001). Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 164: 277–281.
Rossler U, Thomassen E, Hultner L, Baier S, Danescu J, Werenskiold AK . (1995). Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo. Dev Biol 168: 86–97.
Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT . (2007). IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117: 1538–1549.
Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al. (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479–490.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792.
Spencer KS, Graus-Porta D, Leng J, Hynes NE, Klemke RL . (2000). ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J Cell Biol 148: 385–397.
Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia RN et al. (2009). Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene 28: 3047–3057.
Tajima S, Oshikawa K, Tominaga S, Sugiyama Y . (2003). The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 124: 1206–1214.
Tominaga S . (1989). A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 258: 301–304.
Tominaga S, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Komatsu N . (1999). Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun 264: 14–18.
Vial E, Sahai E, Marshall CJ . (2003). ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4: 67–79.
Werenskiold AK, Hoffmann S, Klemenz R . (1989). Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol Cell Biol 9: 5207–5214.
Yarden Y, Sliwkowski MX . (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137.
Zaoui K, Honore S, Isnardon D, Braguer D, Badache A . (2008). Memo-RhoA-mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells. J Cell Biol 183: 401–408.
Acknowledgements
We thank R Marone and N Hynes for support in the preliminary phase of the project, M Lopez and A Gonçalves for helpful discussions, and E Tabone and G Clapisson for providing clinical data. This work was supported by Fondation de France, Association pour la Recherche contre le Cancer and Inserm Avenir Program (AB), Ligue Nationale Contre le Cancer—Label Ligue (DB), INCa grant PL-969-017 « Met-Escape » (NB-V) and fellowships from Fondation de France (JG-D and BD) and Association pour la Recherche sur le Cancer (VS).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Gillibert-Duplantier, J., Duthey, B., Sisirak, V. et al. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene 31, 3516–3524 (2012). https://doi.org/10.1038/onc.2011.525
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.525
Keywords
This article is cited by
-
Copper in Cancer: from transition metal to potential target
Human Cell (2023)
-
Macrophages and cancer stem cells: a malevolent alliance
Molecular Medicine (2021)
-
IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice
Biotechnology Letters (2020)
-
Pleural Effusion IL-33/sST2 Levels and Effects of Low and High IL-33/sST2 Levels on Human Mesothelial Cell Adhesion and Migration
Inflammation (2019)
-
Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients
BMC Cancer (2018)